These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

468 related articles for article (PubMed ID: 34590303)

  • 21. Real-World Evidence of Axicabtagene Ciloleucel for the Treatment of Large B Cell Lymphoma in the United States.
    Jacobson CA; Locke FL; Ma L; Asubonteng J; Hu ZH; Siddiqi T; Ahmed S; Ghobadi A; Miklos DB; Lin Y; Perales MA; Lunning MA; Herr MM; Hill BT; Ganguly S; Dong H; Nikiforow S; Hooper M; Kawashima J; Xu H; Pasquini MC
    Transplant Cell Ther; 2022 Sep; 28(9):581.e1-581.e8. PubMed ID: 35609867
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Axicabtagene ciloleucel vs standard of care in second-line large B-cell lymphoma: outcomes by metabolic tumor volume.
    Locke FL; Oluwole OO; Kuruvilla J; Thieblemont C; Morschhauser F; Salles G; Rowe SP; Vardhanabhuti S; Winters J; Filosto S; To C; Cheng P; Schupp M; Korn R; Kersten MJ
    Blood; 2024 Jun; 143(24):2464-2473. PubMed ID: 38557775
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase 2 study of axicabtagene ciloleucel in Japanese patients with relapsed or refractory large B-cell lymphoma.
    Kato K; Makita S; Goto H; Kanda J; Fujii N; Shimada K; Akashi K; Izutsu K; Teshima T; Fukuda N; Sumitani T; Sumi H; Shimizu S; Kakurai Y; Yoshikawa K; Tobinai K; Usui N; Hatake K
    Int J Clin Oncol; 2022 Jan; 27(1):213-223. PubMed ID: 34599413
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Investigating the Influence of Covariates on Axicabtagene Ciloleucel (axi-cel) Kinetics in Patients with Non-Hodgkin's Lymphoma.
    Chartier M; Filosto S; Peyret T; Chiney M; Milletti F; Budka J; Ndi A; Dong J; Vardhanabhuti S; Mao D; Duffull S; Dodds M; Shen R
    Clin Pharmacokinet; 2024 Sep; 63(9):1283-1299. PubMed ID: 39240498
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma.
    Bachy E; Le Gouill S; Di Blasi R; Sesques P; Manson G; Cartron G; Beauvais D; Roulin L; Gros FX; Rubio MT; Bories P; Bay JO; Llorente CC; Choquet S; Casasnovas RO; Mohty M; Guidez S; Joris M; Loschi M; Carras S; Abraham J; Chauchet A; Drieu La Rochelle L; Deau-Fischer B; Hermine O; Gastinne T; Tudesq JJ; Gat E; Broussais F; Thieblemont C; Houot R; Morschhauser F
    Nat Med; 2022 Oct; 28(10):2145-2154. PubMed ID: 36138152
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Model to Estimate Cytokine Release Syndrome and Neurological Event Management Costs Associated With CAR T-Cell Therapy.
    Badaracco J; Gitlin M; Keating SJ
    Transplant Cell Ther; 2023 Jan; 29(1):59.e1-59.e6. PubMed ID: 36272529
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcomes of CD19-Directed Chimeric Antigen Receptor T Cell Therapy for Transformed Nonfollicular Lymphoma.
    Dong N; Rubio Lopes-Garcia L; Viñal D; Bachmeier C; Shah BD; Nishihori T; Khimani F; Davila ML; Lazaryan A; Pinilla-Ibarz J; Locke FL; Jain MD; Chavez JC
    Transplant Cell Ther; 2023 Jun; 29(6):349.e1-349.e8. PubMed ID: 36878427
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of axicabtagene ciloleucel versus lisocabtagene maraleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the US.
    Oluwole OO; Liu R; Diakite I; Feng C; Patel A; Nourhussein I; Snider JT; Locke FL
    J Med Econ; 2022; 25(1):541-551. PubMed ID: 35443867
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Patterns of Use, Outcomes, and Resource Utilization among Recipients of Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B Cell Lymphomas.
    Riedell PA; Hwang WT; Nastoupil LJ; Pennisi M; McGuirk JP; Maziarz RT; Bachanova V; Oluwole OO; Brower J; Flores OA; Ahmed N; Schachter L; Bharucha K; Dholaria BR; Schuster SJ; Perales MA; Bishop MR; Porter DL
    Transplant Cell Ther; 2022 Oct; 28(10):669-676. PubMed ID: 35850429
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Severity of Cytokine Release Syndrome Influences Outcome After Axicabtagene Ciloleucel for Large B cell Lymphoma: Results from the US Lymphoma CAR-T Consortium.
    Jacobs MT; Jain MD; Gao F; Nastoupil LJ; Spiegel JY; Lin Y; Dahiya S; Lunning M; Lekakis L; Reagan PM; Oluwole OO; McGuirk J; Deol A; Sehgal A; Goy A; Hill BT; Andreadis C; Munoz J; Chavez JC; Bennani NN; Rapoport AP; Vose JM; Miklos DB; Neelapu SS; Ghobadi A; Locke FL
    Clin Lymphoma Myeloma Leuk; 2022 Oct; 22(10):753-759. PubMed ID: 35780055
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
    Abramson JS; Palomba ML; Gordon LI; Lunning MA; Wang M; Arnason J; Mehta A; Purev E; Maloney DG; Andreadis C; Sehgal A; Solomon SR; Ghosh N; Albertson TM; Garcia J; Kostic A; Mallaney M; Ogasawara K; Newhall K; Kim Y; Li D; Siddiqi T
    Lancet; 2020 Sep; 396(10254):839-852. PubMed ID: 32888407
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparing Efficacy, Safety, and Preinfusion Period of Axicabtagene Ciloleucel versus Tisagenlecleucel in Relapsed/Refractory Large B Cell Lymphoma.
    Oluwole OO; Jansen JP; Lin VW; Chan K; Keeping S; Navale L; Locke FL
    Biol Blood Marrow Transplant; 2020 Sep; 26(9):1581-1588. PubMed ID: 32561336
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma.
    Kwon M; Iacoboni G; Reguera JL; Corral LL; Morales RH; Ortiz-Maldonado V; Guerreiro M; Caballero AC; Domínguez MLG; Pina JMS; Mussetti A; Sancho JM; Bastos-Oreiro M; Catala E; Delgado J; Henriquez HL; Sanz J; Calbacho M; Bailén R; Carpio C; Ribera JM; Sureda A; Briones J; Hernandez-Boluda JC; Cebrián NM; Martin JLD; Martín A; Barba P
    Haematologica; 2023 Jan; 108(1):110-121. PubMed ID: 35770532
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase 2 study of axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma in Japan: 1-year follow-up and biomarker analysis.
    Kato K; Fujii N; Makita S; Goto H; Kanda J; Shimada K; Akashi K; Izutsu K; Teshima T; Fukuda N; Sumitani T; Nakamura S; Sumi H; Shimizu S; Kakurai Y; Yoshikawa K; Tobinai K; Usui N; Hatake K
    Int J Hematol; 2023 Mar; 117(3):409-420. PubMed ID: 36399286
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness of treating relapsed or refractory 3L+ follicular lymphoma with axicabtagene ciloleucel vs mosunetuzumab in the United States.
    Oluwole OO; Ray MD; Zur RM; Ferrufino CP; Doble B; Patel AR; Bilir SP
    Front Immunol; 2024; 15():1393939. PubMed ID: 38855109
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma.
    Neelapu SS; Jacobson CA; Ghobadi A; Miklos DB; Lekakis LJ; Oluwole OO; Lin Y; Braunschweig I; Hill BT; Timmerman JM; Deol A; Reagan PM; Stiff P; Flinn IW; Farooq U; Goy AH; McSweeney PA; Munoz J; Siddiqi T; Chavez JC; Herrera AF; Bartlett NL; Bot AA; Shen RR; Dong J; Singh K; Miao H; Kim JJ; Zheng Y; Locke FL
    Blood; 2023 May; 141(19):2307-2315. PubMed ID: 36821768
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma.
    Westin JR; Oluwole OO; Kersten MJ; Miklos DB; Perales MA; Ghobadi A; Rapoport AP; Sureda A; Jacobson CA; Farooq U; van Meerten T; Ulrickson M; Elsawy M; Leslie LA; Chaganti S; Dickinson M; Dorritie K; Reagan PM; McGuirk J; Song KW; Riedell PA; Minnema MC; Yang Y; Vardhanabhuti S; Filosto S; Cheng P; Shahani SA; Schupp M; To C; Locke FL; ;
    N Engl J Med; 2023 Jul; 389(2):148-157. PubMed ID: 37272527
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5).
    Neelapu SS; Chavez JC; Sehgal AR; Epperla N; Ulrickson M; Bachy E; Munshi PN; Casulo C; Maloney DG; de Vos S; Reshef R; Leslie LA; Oluwole OO; Yakoub-Agha I; Khanal R; Rosenblatt J; Korn R; Peng W; Lui C; Wulff J; Shen R; Poddar S; Jung AS; Miao H; Beygi S; Jacobson CA
    Blood; 2024 Feb; 143(6):496-506. PubMed ID: 37879047
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dermatologic Adverse Events Associated With Chimeric Antigen Receptor T-Cell Therapy: A Pharmacovigilance Analysis of the FDA Reporting System.
    Storgard R; Dusza S; Shouval R; Scordo M; Markova A
    Transplant Cell Ther; 2024 Oct; 30(10):1035.e1-1035.e7. PubMed ID: 38945480
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FDA Approval Summary: Axicabtagene Ciloleucel for Second-Line Treatment of Large B-Cell Lymphoma.
    Sharma P; Kasamon YL; Lin X; Xu Z; Theoret MR; Purohit-Sheth T
    Clin Cancer Res; 2023 Nov; 29(21):4331-4337. PubMed ID: 37405396
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.